Findings demonstrate promising in vitro anticancer activity of CuFe2O4 nanoparticles using an aqueous leaf extract of Artemisia argyi through a green, eco-friendly route.
Abstract
Cancer remains the second leading cause of death worldwide, and two inherent challenges in conventional therapies, indiscriminate toxicity and development of drug resistance by cancer cells, have increased the demand for novel therapeutic means. In this study, copper ferrite (CuFe2O4) nanoparticles were synthesized using an aqueous leaf extract of Artemisia argyi through a green, eco-friendly route. The synthesized nanoparticles were characterized by XRD, SEM-EDX, and FTIR to reveal their crystalline spinel structure, spherical morphology, and functional group composition. The average crystallite size was 15.25 ± 6.48 nm. Cytotoxic potential of the particles was assessed using three different cell lines, MCF-7 (breast), A549 (lung), and L929, (normal fibroblast). MTT assays revealed a dose- and time-dependent reduction in cancer cell viability. Highest sensitivity was demonstrated by MCF-7 cells. Exposure to the particles also appeared to have caused changes in the expression levels of some of the key genes involved in cell survival: Caspase-3 and BAX, for which a meaningful increase was observed, while the amount of BCL-2 decreased. Such an activity pattern suggested apoptosis as the primary pathway in cell death. Flow cytometry results further unraveled the role of late apoptosis in MCF-7 cells. Importantly, the nanoparticles showed lower cytotoxicity toward L929 cells, indicating a degree of selectivity for cancer cells. These findings demonstrate promising in vitro anticancer activity of CuFe2O4 nanoparticles. Gibbs free energy changes of the complexes formed by some of the Artemisia argyi molecules and copper ferrite nanoparticles were investigated using the Gaussian software package in B3LYP, HF, and M06-2x method at 6-31 + + g(d,p) basis set. The activities of four of the molecules, having very high negative Gibbs free energies, against breast and lung cancer proteins were compared.
Introduction Chronic hormonal imbalances and associated symptoms characterize ovarian cancer. PARP-1 inhibitors, such as olaparib and ruparib, are used to treat it, but new drugs are needed to overcome toxicity and resistance issues. PARP inhibition in BRCA1/2-mutated cancer cells leads to apoptosis. Methods We synthes...
Sangita Dey, K. Wadhwa, Neha Kumari et al.· Frontiers in Pharmacology· 0 citations
Gold nanoparticles (GNPs) are metallic structures that have been widely studied owing to their outstanding physicochemical properties it can be implemented for biomedical applications. The synthesis process includes chemical, physical, and biological methods. However, green chemistry has received much attention for t...
R. Manisekaran, M. Figueroa, Mariano Jácome Rebollo et al.· Particle & Particle Syst...· 0 citations
Findings establish M. crystallinum as an ecologically sustainable nanofactory whose stress-adapted metabolome directs the formation of selectively cytotoxic ZnO-NPs acting through ROS-mediated mitochondrial dysfunction, a paradigm for designing plant-guided nanotherapeutics with defined molecular mechanisms.
S. Taha, N. Emam, S. Salem et al.· Bioresources and Bioprocessi...· 0 citations
The green synthesis of silver nanoparticles (PV-Ag NPs) using a pigment-producing environmental fungus, Penicillium verrucosum (PV) RPF011, as a biological reducing and stabilizing agent highlights the potential of P. verrucosum-mediated silver nanoparticles as an eco-friendly and cost-effective nanoplatform with dual...
Antibiotic resistance is a major health challenge in the world today. This has created the need for the development of other forms of antimicrobial therapies. In this study, silver nanoparticles (AgNPs) were synthesized using the aqueous extract of cumin seeds (Cuminum cyminum) as the reducing and capping agents. Co...
Aseel Alsamarraie, Warqaa Latef Salman, Shefaa Abas· Journal of Education for Pur...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.